From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement

Electronic health record-based nudge intervention and axillary surgery in older women with breast cancer: A nonrandomized controlled trial

Last Updated: Thursday, September 19, 2024

Although Choosing Wisely recommendations advocate against the use of sentinel lymph node biopsy (SLNB) use in older women with early-stage, clinically node-negative, and HR+ HER2- breast cancer, it is a practice that is still widely used. To combat this overuse, investigators used an electronic health record–based nudge intervention that targeted surgeons in their first outpatient visit with patients in this population. During the nudge intervention period, unadjusted rates of SLNB decreased by 23.1 percentage points compared with rates during the control period. The investigators concluded that the nudge intervention was easily implementable and could help decrease low-value care both in this and other settings.  

JAMA Surgery
Advertisement
News & Literature Highlights

The Breast

Awareness of genomic testing among patients with breast cancer in Europe

BMC Women’s Health

Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: A meta-analysis

npj Precision Oncology

Successful unconventional precision treatment of inflammatory hormone receptor-positive breast cancer guided by molecular profiling

Cancer Treatment Reviews

First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?

European Journal of Nuclear Medicine and Molecular Imaging

Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors

Chinese Journal of Cancer Research

Clinicopathological and molecular features of HR + /HER2 - breast cancer patients with distinct endocrine resistance patterns

Cancer Cell

CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety

Breast Cancer Research and Treatment

PTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence

Journal of Cachexia, Sarcopenia, and Muscle

Low skeletal muscle radiodensity predicts response to CDK4/6 inhibitors plus aromatase inhibitors in advanced breast cancer

European Journal of Cancer

Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer

Advertisement
Advertisement